Answers are grounded in this paper and cite their sources.
In situ vaccination (ISV) is an established and growing cancer therapy strategy.Preclinical studies show that ISV antitumor efficacy is achievable by of plant virus nanoparticles (PVNPs), in which PVNPs are directly administered into the tumor.It had previously shown that some PVNPs are potent in inducing long-lasting antitumor immunity when used as an in situ vaccine.Here, we investigate a filamentous plant virus nanoparticle, potato virus Y (PVY), for in situ vaccination treatment of 4T1, the very aggressive and metastatic murine triple-negative breast cancer model.PVY used as ISV does not significantly slow down tumor progression.Data indicate that some PVNPs are more suitable for application as in situ vaccines than others; understanding the intricate differences and underlying mechanisms of immune-activation may set the stage for clinical development of these technologies.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: